肿瘤药学2019，Vol.9Issue(2)：280-283,4.DOI:10.3969/j.issn.2095-1264.2019.02.21
小剂量阿帕替尼逆转晚期NSCLC第一代EGFR-TKIs继发性耐药临床研究
The Clinical Study of Low Dose Apatinib in Reversing Acquired Resistance of Advanced NSCLC to First-Generation EGFR-TKIs
CHEN Mingda 1LIU Weidong 1HU Wenjian 1SONG Junli1
作者信息
- 1. Tangshan People’s Hospital, Tangshan, Hebei, 063001, China
- 折叠
摘要
Abstract
Objective To investigate the efficacy and safety of low dose apatinib plus original targeted drug for patients with advanced non-small cell lung cancer (NSCLC) and acquired resistance to first-generation epithelial growth factor receptor - tyrosine kinase inhibi-tors (EGFR-TKIs). Methods Between March 2016 and November 2016, 11 advanced NSCLC patients with acquired resistance to erlotinib, gefitinib or icotinib were treated with original targeted drug plus oral administration of apatinib, 250 mg, once daily. Patients had CT scan every 4 weeks. Observe the related toxic and side effects in the meanwhile. Results Of the 11 patients, two cases had disease progress within 12 weeks, one case had drug withdrawal by himself. Eight cases had disease controlled and remain in treatment. The median time to progress (TTP) was 12 weeks. One case had proteinuria 3+, and two cases appeared rash, and two cases felt fatigue, and two cases lost their appetite. Conclusion The low dose apatinib plus original targeted drug had good efficacy and tolerated side effects on advanced NSCLC patients with acquired resistance to first-generation EGFR-TKIs.关键词
阿帕替尼/晚期NSCLC/EGFR-TKIs/继发性耐药Key words
Apatinib/Advanced NSCLC/EGFR-TKI/Acquired resistance分类
医药卫生引用本文复制引用
CHEN Mingda,LIU Weidong,HU Wenjian,SONG Junli..小剂量阿帕替尼逆转晚期NSCLC第一代EGFR-TKIs继发性耐药临床研究[J].肿瘤药学,2019,9(2):280-283,4.
